CDMO Fujifilm Diosynth's restructuring plan may leave up to 240 staffers out of work

Fujifilm Diosynth Biotechnologies' venture into separate small-scale and large-scale business units doesn't appear to be working out as planned.

Tuesday, the CDMO revealed that it's reworking its small-scale business unit after taking hits from “the short-term impacts of reduced venture capital investment into early-stage research projects,” Fujifilm Diosynth said in a recent business update.